Can innovation still be the main growth driver of the pharmaceutical industry?
- In the period from the 1950s to 2013, the American Food and Drug Administration (FDA) approved 1346 new molecular entities (NMEs) or new biologics entities (NBEs). On average, the approval rate was 20 NMEs per year. In the past 40 years, the number of new drugs launched into the market increased slightly from 15 NMEs in the 1970s to 25–30 NMEs since the 1990s. The highest number of new drugs approved by FDA was in 1996 and 1997, which might be related to the enactment of the Prescription Drug User Fee Act (PDUFA) in 1993.
| Author of HS Reutlingen | Schuhmacher, Alexander |
|---|---|
| DOI: | https://doi.org/10.1007/978-3-319-12526-8_2 |
| ISBN: | 978-3-319-12525-1 |
| Erschienen in: | Sustainable Development for the Healthcare Industry : Reprogramming the Healthcare Value Chain |
| Publisher: | Springer |
| Place of publication: | Cham |
| Editor: | Pierre Morgon |
| Document Type: | Book chapter |
| Language: | English |
| Publication year: | 2014 |
| Page Number: | 30 |
| First Page: | 39 |
| Last Page: | 68 |
| PPN: | Im Katalog der Hochschule Reutlingen ansehen |
| DDC classes: | 610 Medizin, Gesundheit |
| Open access?: | Nein |
| Licence (German): |  In Copyright - Urheberrechtlich geschützt |
